Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury
NCT06548802Phase 2Active, not recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in not applicable; "lung injury" is not a specific disease, acute respiratory distress syndrome (ARDS), sponsored by Tianjin Medical University General Hospital. Started Feb 2024; status: active, not recruiting.
02
Drugs
baricitinib
03
Conditions
not applicable; "lung injury" is not a specific diseaseacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT06548802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548802.